UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 7, 2006
----------------
A.P. Pharma, Inc.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
000-16109
------------------------
(Commission File Number)
Delaware 94-2875566
- ---------------------------- -------------------
(State or other jurisdiction (I.R.S. Employer
of incorporation) Identification No.)
123 Saginaw Drive
Redwood City, CA 94063
-------------------------------------------------------
(Address of principal executive offices, with zip code)
(650) 366-2626
----------------------------------------------------
(Registrant's telephone number, including area code)
N/A
------------------------------------------------------------
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the
registrant under any of the following provisions (see General
Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 2.02 Results of Operations and Financial Condition
On November 7, 2006, the Registrant issued a press release
announcing its financial results for the third quarter ended
September 30, 2006. The press release is attached as Exhibit
99.1.
The information in this Current Report on Form 8-K, including
the exhibit, is furnished pursuant to Item 2.02 and shall not be
deemed "filed" for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the
liabilities under that Section. Furthermore, the information in
the Current Report on Form 8-K, including the exhibit, shall not
be deemed to be incorporated by reference into the filings of
the Company under the Securities Act of 1933, as amended.
ITEM 9.01 Financial Statements and Exhibits.
(C) Exhibits
99.1 Press release dated November 7, 2006.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
A.P. Pharma, Inc.
Date: November 7, 2006 By: /S/ Stephen C. Whiteford
---------------- ------------------------
Stephen C. Whiteford
Vice President, Finance
and Chief Financial
Officer
EXHIBIT INDEX
99.1 Press release dated November 7, 2006